ArticleACS omega2026
Enhanced Expansion of Bone Marrow-Derived Mesenchymal Stem Cells on Collagen-Coated Microcarriers Functionalized with Chimeric IGF-1-bFGF Proteins.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stem cells (hMSCs) are promising for cell transplantation therapies. Nevertheless, their limited yield necessitates large-scale ex vivo expansion. Microcarrier-based culture offers a scalable platform, but efficient functionalization strategies are not available. Here, we engineered collagen-binding chimeric proteins by fusing insulin-like growth factor-1 (IGF-1) and basic fibroblast growth factor (bFGF) with an osteopontin-derived collagen-binding peptide and immobilized them on type I collagen-coated poly-(vinyl alcohol) microcarriers. This single-molecule design provides the unique advantage where the surface is functionalized with a fixed molar ratio of IGF-1 to bFGF, avoiding the stoichiometric uncertainty inherent to the coimmobilization of separate proteins. Structural characterization confirmed proper folding of the chimeras, and functional assays demonstrated that dual-domain constructs markedly enhanced hMSC proliferation compared with single-factor controls, with the IGF-1-bFGF chimera yielding the highest effect. Expanded cells retained osteogenic differentiation potential. These findings demonstrate that chimeric growth factors with defined stoichiometry offer a practical and robust strategy for scalable hMSC expansion, with significant implications for regenerative medicine and cell therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.